RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @giovannilandoni: 6/ We were the first ones to administer the vasoconstrictor angiotensin II in #COVID19 patients and to share the findi…
6/ We were the first ones to administer the vasoconstrictor angiotensin II in #COVID19 patients and to share the findings. https://t.co/DPApzzChfu
@abledoc
RT @FagerlundMalin: Should COVID-19 ICU patients really receive angiotensin II for vasodilatory chock? https://t.co/nYC1lsOC68
RT @FagerlundMalin: Should COVID-19 ICU patients really receive angiotensin II for vasodilatory chock? https://t.co/nYC1lsOC68
RT @FagerlundMalin: Should COVID-19 ICU patients really receive angiotensin II for vasodilatory chock? https://t.co/nYC1lsOC68
”the administration of ANGII was associated with achievement and maintenance of target MAP, an increase on SpO2/FiO2 ratio, and a decrease in FiO2. These oxygenation improvements were significant” Thoughts?? @CriticalCareNow @MedCrisis @cameronks @Crit_Car
RT @stairspunktse: Angiotensin II är ett behandlingsalternativ vid septisk/distributiv shock. Hur är det vid COVID-19?
RT @FagerlundMalin: Should COVID-19 ICU patients really receive angiotensin II for vasodilatory chock? https://t.co/nYC1lsOC68
RT @FagerlundMalin: Should COVID-19 ICU patients really receive angiotensin II for vasodilatory chock? https://t.co/nYC1lsOC68
Angiotensin II är ett behandlingsalternativ vid septisk/distributiv shock. Hur är det vid COVID-19?
RT @FagerlundMalin: Should COVID-19 ICU patients really receive angiotensin II for vasodilatory chock? https://t.co/nYC1lsOC68
Should COVID-19 ICU patients really receive angiotensin II for vasodilatory chock? https://t.co/nYC1lsOC68
@jimcramer $LJPC drug working really well for critically ill #covid19 patients but company is focused on the science not promoting the stock (which I get but sucks for short term action!) https://t.co/Rz7o7XkMsp
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @tscquizzato: If you want to learn more about the use of Angiotensin II in ventilated #COVID19 pts with vasodilatory shock read this cas…
RT @PropThinker: Milan Hospital Study: $LJPC Giapreza was associated with oxygenation improvements and maintenance of target MAP in severe…
Milan Hospital Study: $LJPC Giapreza was associated with oxygenation improvements and maintenance of target MAP in severe #COVID patients https://t.co/31tmQpsYbR
RT @tscquizzato: If you want to learn more about the use of Angiotensin II in ventilated #COVID19 pts with vasodilatory shock read this cas…
If you want to learn more about the use of Angiotensin II in ventilated #COVID19 pts with vasodilatory shock read this case series from @SRAnesthesiaICU 👇 #FOAMed #FOAMcc #COVID19FOAM
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
@Varro_Analytics @juliaskripkaser Looks like he nailed the LJPC .... https://t.co/Rz7o7XkMsp
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
#Giapreza $LJPC #angiotensinII #ATII #covid-19 Giapreza working well as a pressor and can buy doctors time to treat underlying cause. After all a #vasopressor increases blood pressure and this drug does that well.. The improvement in gas exchange is 😳http
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
RT @SRAnesthesiaICU: We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 6…
We treated 16 ventilated #COVID19 patients in vasodilatory shock with Angiotensin II (20 ng/kg/min titrated to MAP > 65 mmHg). ANGII achieved target MAP, we observed increased SpO2/FiO2 ratio. At 1 week 14 patients were alive. https://t.co/xj4ktDtOJO #F